Skip Navigation



Brain Advance Access published online on October 3, 2006
Brain, doi:10.1093/brain/awl280
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
129/11/2840    most recent
awl280v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Klafki, H.-W.
Right arrow Articles by Wiltfang, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klafki, H.-W.
Right arrow Articles by Wiltfang, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commerical License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received July 4, 2006
Revised August 25, 2006
Accepted August 31, 2006

Review Article

Therapeutic approaches to Alzheimer's disease

Hans-Wolfgang Klafki 1, Matthias Staufenbiel 2, Johannes Kornhuber 1, and Jens Wiltfang 1 *

1 Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany
2 Novartis Institutes for Biomedical Research, Basel, Switzerland

* To whom correspondence should be addressed.
Jens Wiltfang, E-mail: jens.wiltfang{at}psych.imed.uni-erlangen.de


  Abstract

Alzheimer's disease is an age-related progressive neurodegenerative disorder with an enormous unmet medical need. It is the most common form of dementia affecting ~5% of adults over 65 years. In view of our ageing society the number of patients, as well as the economical and social impact, is expected to grow dramatically in the future. Currently available medications appear to be able to produce moderate symptomatic benefits but not to stop disease progression. The search for novel therapeutic approaches targeting the presumed underlying pathogenic mechanisms has been a major focus of research and it is expected that novel medications with disease-modifying properties will emerge from these efforts in the future. In this review, currently available drugs as well as novel therapeutic strategies, in particular those targeting amyloid and tau pathologies, are discussed.

Keywords: amyloid plaques; neurofibrillary tangles; tau pathology; therapeutic strategies.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 AM J ALZHEIMERS DIS OTHER DEMENHome page
L. Minati, T. Edginton, M. Grazia Bruzzone, and G. Giaccone
Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review
American Journal of Alzheimer's Disease and Other Dementias, April 1, 2009; 24(2): 95 - 121.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
K. E. Paleologou, A. W. Schmid, C. C. Rospigliosi, H.-Y. Kim, G. R. Lamberto, R. A. Fredenburg, P. T. Lansbury Jr., C. O. Fernandez, D. Eliezer, M. Zweckstetter, et al.
Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of {alpha}-Synuclein
J. Biol. Chem., June 13, 2008; 283(24): 16895 - 16905.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. J. Wruck, M. E. Gotz, T. Herdegen, D. Varoga, L.-O. Brandenburg, and T. Pufe
Kavalactones Protect Neural Cells against Amyloid {beta} Peptide-Induced Neurotoxicity via Extracellular Signal-Regulated Kinase 1/2-Dependent Nuclear Factor Erythroid 2-Related Factor 2 Activation
Mol. Pharmacol., June 1, 2008; 73(6): 1785 - 1795.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
N. Nelissen, M. Vandenbulcke, K. Fannes, A. Verbruggen, R. Peeters, P. Dupont, K. Van Laere, G. Bormans, and R. Vandenberghe
A{beta} amyloid deposition in the language system and how the brain responds
Brain, August 1, 2007; 130(8): 2055 - 2069.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.